rs113488022
|
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
The BRAF gene has been identified as an oncogene in human cancer and the V600E mutation has been shown to be associated with clinico pathological features of primary invasive melanomas.
|
21262211 |
2011 |
rs113488022
|
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
The BRAF (V600E) mutation is found in several human cancer, causing an increase of cell proliferation due to a modification of the ERK/MAPK-signal cascade.
|
31762942 |
2019 |
rs113488022
|
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
The usefulness of immunohistochemistry (IHC) as a new approach for the detection of BRAF V600E in cancer patients has been recently reported.
|
23927882 |
2013 |
rs113488022
|
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Overall, our results suggest that DETD-35 may be useful as a therapeutic or adjuvant agent against BRAF(V600E) mutant and acquired vemurafenib resistance melanoma.Mol Cancer Ther; 15(6); 1163-76.©2016 AACR.
|
27048951 |
2016 |
rs113488022
|
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
We used a polymerase chain reaction-based assay to detect mutations in BRAF (V600E) and in KRAS in 2720 stage III cancer samples, collected prospectively from patients participating in an adjuvant chemotherapy trial (NCCTG N0147).
|
25305506 |
2015 |
rs113488022
|
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Interesting, Prof. Peng Hou and colleagues, at the First Affiliated Hospital of Xi'an Jiaotong University in China, identified unknown epigenetic mechanisms and their involvement in the tumorigenesis of B-RAF(V600E)-driven cancer.
|
28638488 |
2017 |
rs113488022
|
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
The aim of the correlative tumour tissue studies was to investigate the relationship between EGFR gene copy numbers, activation of the EGFR pathway, expression and mutation of E-cadherin, V600E BRAF mutation and clinical outcome of patients with gastric and OGJ cancer treated with cetuximab combined with FUFOX.
|
22152101 |
2011 |
rs113488022
|
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
The aims of this study were to evaluate the utility of US-guided FNAB in the diagnostic assessment of nodules with or without clinical/US features suggestive for malignancy and to investigate the additional contribution of BRAF V600E mutation analysis in the detection of differentiated thyroid cancer.
|
22535974 |
2012 |
rs113488022
|
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Patients with this cancer have a high frequency (~50%) of oncogenic <i>BRAF</i> mutations, particularly BRAF V600E.
|
29387237 |
2018 |
rs113488022
|
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Evidence has also shown that the detection of the BRAF(V600E) mutation in cancer is crucial in order to identify novel avenues for thyroid cancer treatment.Based on the BRAF kinase structure, novel drugs can potentially be designed to target oncogenic BRAF in cancer therapeutics.
|
25961545 |
2015 |
rs113488022
|
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Detection of the BRAF V600E mutation is therefore a useful adjunct in the differential diagnosis of HCL and HCL variant and highlights the value of a multifaceted approach to the diagnosis of this malignancy.
|
22313586 |
2012 |
rs113488022
|
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
The BRAF inhibitor vemurafenib has become an important treatment option for melanoma patients, the majority of whom have a BRAF(V600E) mutation driving their malignancy.
|
23074264 |
2012 |
rs113488022
|
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
We calculated and compared the diagnostic performances of cytology and cytology with BRAF(V600E) mutation analysis to detect malignancy among thyroid nodules according to ultrasound features and size.
|
23717622 |
2013 |
rs113488022
|
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Testing for BRAF (V600E) Mutation in Thyroid Nodules with Fine-Needle Aspiration (FNA) Read as Suspicious for Malignancy (Bethesda V, Thy4, TIR4): a Systematic Review and Meta-analysis.
|
31811566 |
2020 |
rs113488022
|
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
This study sought to determine if cytologic markers of malignancy are associated with the BRAF(V600E) mutation and if preoperative BRAF(V600E) testing would alter the initial management of patients with indeterminate nodules.
|
23280049 |
2013 |
rs113488022
|
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Hence, this IHC detection is sensitive for clinic uses as a simple, fast, inexpensive, and reliable method to screen cancer patients for the BRAF(V600E) mutation and could be easily adapted for use in most hospital pathology laboratories.
|
24563339 |
2014 |
rs113488022
|
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Furthermore, RAS function is not required for the growth of cancer cell lines with the V599E mutation.
|
12068308 |
2002 |
rs113488022
|
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Identification of BRAF(V600E) in thyroid neoplasia may be useful because it is specific for malignancy, connotes a worse prognosis, and is the target of novel therapies currently under investigation.
|
22997209 |
2012 |
rs113488022
|
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF(V600E) phosphorylates and activates the MEK1 and MEK2 kinases, which in turn phosphorylate and activate the ERK1 and ERK2 kinases, stimulating the mitogen-activated protein kinase (MAPK) pathway to promote cancer.
|
24717435 |
2014 |
rs113488022
|
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
These data demonstrate that clonal BRAF(V600E) is a rare occurrence in PTC, although frequently this cancer consists of a mixture of tumor cells with wild-type and mutant BRAF.
|
22170714 |
2012 |
rs113488022
|
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF-V600E mutations are found in a broad spectrum of cancer types and can be successfully targeted by specific therapeutic compounds.
|
23343956 |
2013 |
rs113488022
|
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
In serrated adenomas, BRAF-V600E mutation does not seem to be associated with age and sex, with the prevalence of dysplasia and cancer and with the morphology of the dysplastic component.
|
30815911 |
2019 |
rs113488022
|
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
The V600E mutation accounts for most of the BRAF mutations in cancer, and KRAS mutations are predominantly encoded by nucleotide substitutions within codons 12 and 13.
|
19430299 |
2009 |
rs113488022
|
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
None of the 504 benign, 45 (31.9%) of the 141 ACUS, 46 (85.2%) of the 54 suspicious for malignancy, 129 (92.1%) of the 140 malignant, and one (10%) of the 10 suspicious for follicular neoplasm cases showed BRAF(V600E) mutation.
|
21239517 |
2011 |
rs113488022
|
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
The purpose of this study was to evaluate the feasibility of core-needle biopsy with BRAF(V600E) mutation analysis (CNB + BRAF(V600E) ) and to compare the clinical usefulness of CNB + BRAF(V600E) and fine-needle aspiration with BRAF(V600E) mutation analysis (FNA + BRAF(V600E) ) in the diagnosis of thyroid malignancy.
|
26215382 |
2016 |